Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.41), reports. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative return on equity of 280.95%. The business had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.20 million.
Armata Pharmaceuticals Stock Performance
Shares of NYSEAMERICAN ARMP traded down $0.14 during trading hours on Friday, reaching $3.12. The stock had a trading volume of 3,967 shares, compared to its average volume of 16,744. Armata Pharmaceuticals has a 52-week low of $1.07 and a 52-week high of $5.26. The firm has a market capitalization of $112.79 million, a price-to-earnings ratio of -1.62 and a beta of 0.96.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a report on Wednesday.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC increased its position in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) by 80.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,777 shares of the company’s stock after acquiring an additional 14,647 shares during the quarter. SeaCrest Wealth Management LLC owned about 0.09% of Armata Pharmaceuticals worth $137,000 as of its most recent SEC filing. Institutional investors and hedge funds own 3.57% of the company’s stock.
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Further Reading
- Five stocks we like better than Armata Pharmaceuticals
- What is a Secondary Public Offering? What Investors Need to Know
- Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
- Overbought Stocks Explained: Should You Trade Them?
- Unity Software’s Mixed Q1, But Long-Term Outlook Remains Positive
- What is Forex and How Does it Work?
- JFrog Stock Gets Punished for Solid Results: Buy the Dip
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
